Literature DB >> 15528941

Could plasma cystatin C be useful as a marker of hemodialysis low molecular weight proteins removal?

Andrea Campo1, Giacomo Lanfranco, Luciana Gramaglia, Franco Goia, Roberto Cottino, Viglino Giusto.   

Abstract

BACKGROUND: Plasma cystatin (pCyst) is a well-assessed tool for measuring renal function, and it could also play a part in hemodialysis adequacy.
METHODS: pCyst and other uremic toxins (urea, creatinine, parathyroid hormone, prolactin) were assessed before and after a dialysis session in 18 hemodialysis patients: 7 on bicarbonate hemodialysis (BHD) and 11 on mixed convective dialysis (MCD; 6 standard hemodiafiltration and 5 acetate-free biofiltration). Plasma levels and reduction ratios (RR) were then compared between the BHD and MCD groups.
RESULTS: The mean pre-dialysis pCyst level is nearly the same in both groups (5.3 +/- 0.8 vs. 5.7 +/- 1 mg/l, p = ns), although a substantial decrease occurs after MCD only (mean 2.4 +/- 1 vs. 6.2 +/- 2.2 mg/l after BHD, p = 0.002). The mean pCyst RR (PCRR) of 55.5% after MCD is poorly related to prolactin and urea RR, fairly comparable to parathyroid hormone RR and very close to creatinine RR (58.4%).
CONCLUSIONS: Only MCD removes pCyst, but the amount of removal is different for other low molecular weight proteins (prolactin and parathyroid hormone) and similar for creatinine, a classic 'little molecule'. In view of the discrepancy of these findings, the use of pCyst in hemodialysis still seems premature and needs further studies. Copyright (c) 2004 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15528941     DOI: 10.1159/000080677

Source DB:  PubMed          Journal:  Nephron Clin Pract        ISSN: 1660-2110


  6 in total

Review 1.  Normal and pathologic concentrations of uremic toxins.

Authors:  Flore Duranton; Gerald Cohen; Rita De Smet; Mariano Rodriguez; Joachim Jankowski; Raymond Vanholder; Angel Argiles
Journal:  J Am Soc Nephrol       Date:  2012-05-24       Impact factor: 10.121

2.  Removal and rebound kinetics of cystatin C in high-flux hemodialysis and hemodiafiltration.

Authors:  Enric Vilar; Capella Boltiador; Adie Viljoen; Ashwini Machado; Ken Farrington
Journal:  Clin J Am Soc Nephrol       Date:  2014-05-01       Impact factor: 8.237

3.  Levels of cystatin C in low- and high-flux hemodialysis in children with end-stage renal disease.

Authors:  Fatina I Fadel; Abbass A Mourad; Azza M O Abdel Rahman; Hafez M Bazaraa; Mohamed Farouk Mohamed; Dalia H El-Lebedy; Mohamed M Soliman
Journal:  Pediatr Nephrol       Date:  2017-04-17       Impact factor: 3.714

4.  Application of cystatin C reduction ratio to high-flux hemodialysis as an alternative indicator of the clearance of middle molecules.

Authors:  Joon-Sung Park; Gheun-Ho Kim; Chong Myung Kang; Chang Hwa Lee
Journal:  Korean J Intern Med       Date:  2010-02-26       Impact factor: 3.165

5.  Effect of hemodialysis on circulating cystatin c levels in patients with end stage renal disease.

Authors:  N Krishnamurthy; K Arumugasamy; U Anand; C V Anand; V Aruna; G Venu; R Gayathri
Journal:  Indian J Clin Biochem       Date:  2010-02-10

6.  Cystatin C: An alternative dialysis adequacy marker in high flux hemodialysis.

Authors:  K U Maheshwari; S Santhi; R J Malar
Journal:  Indian J Nephrol       Date:  2015 May-Jun
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.